15%
Anastomotic leakage in lower rectum resection today
Anastomotic leakage in lower rectum resection today
Target leakage rate with the Avistal instrument
Of surgical insight and pre-clinical work behind the design
Twenty years of animal and human trials shaped a final design that fits the anatomy of the low pelvis, supports a reliable anastomosis, and gives surgeons a predictable result in the most demanding part of colorectal oncology.


Target 3% anastomotic leakage versus today's 15% in low rectum cases.
Geometry designed specifically for the narrow lower pelvis.
Eliminates reprocessing variability between procedures.
Predictable handling shortens the critical steps of the anastomosis.

Conventional staplers and clamps were designed for the abdomen, not the narrow confines of the low pelvis. The Avistal device is shaped around the surgical field — improving tissue handling at the precise step where leakage occurs.
Designed to reach the deep pelvis without compromising visibility or control.
Anatomy-matched geometry stabilises tissue at the anastomotic site.
Engineered to deliver a reproducible, low-tension anastomosis.
Single-use removal leaves nothing to reprocess between patients.


Thomas Hellström
Leads business strategi, communication, organisation, engineering and product development.
Drives company strategy, fundraising and commercial partnerships across the Nordics.
Leads quality assurance, regulatory compliance, and continuous improvement initiatives, bringing extensive MedTech industry experience across quality systems, audits, and product lifecycle management.
A network of experienced surgeons providing clinical insight and validating device requirements from the operating theatre.
Avistal Nordic AB is headquartered in Sweden and works with clinical partners across the Nordics to validate every iteration of the device against real operating-room demands.
